

Sun Pharmaceutical Industries Ltd  
 Plot No. 10, Sector 10, Gurgaon  
 Haryana - 122001, India  
 Tel: +91 122 66455685  
 Fax: +91 122 66455686  
 Email: [info@sunpharma.com](mailto:info@sunpharma.com)



**FOR IMMEDIATE RELEASE**

**Sun Pharma: An update on generic Protonix® litigation**

Mumbai, February 15, 2012: Sun Pharmaceutical Industries Ltd ("Sun Pharma", also together with its subsidiaries) announces that in the ongoing litigation pending in the United States District Court of District of New Jersey ("the District Court") regarding Sun Pharma subsidiary's and Teva's ("defendants") generic pantoprazole products, Wyeth has submitted to the District Court confidential expert reports claiming damages arising out of defendants earlier at-risk launches. Earlier in 2010, the District Court had denied defendants motion for judgment as a matter of law seeking to reverse the jury verdict that the patent is not invalid. The District Court is yet to rule on patent misuse.

Wyeth's experts have estimated the purported damages from Sun Pharma to be \$ 960 million. Wyeth's experts have also claimed Teva may be liable for some of Sun Pharma's damages and vice versa.

In due course, Sun Pharma will also serve upon the parties Sun Pharma's expert reports providing its own assessment on the purported damages. After this, patent misuse and appropriate level of damages will be determined. Sun Pharma believes that it has sound reasons to disagree with these overstated claims of Wyeth, and also continues to believe that the patent is invalid and unenforceable and will pursue all available legal remedies including appeals.

*Protonix® is a registered trademark of Wyeth Pharmaceuticals, Inc.*

**About Sun Pharma**

Established in 1983, listed since 1994 and headquartered in India, Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at [www.sunpharma.com](http://www.sunpharma.com).

**Contacts**

Uday Baldota  
 Tel +91 22 6645 5645, Xtn 605  
 Tel Direct +91 22 66455605  
 Mobile +91 98670 10529  
 E mail [uday.baldota@sunpharma.com](mailto:uday.baldota@sunpharma.com)

Mira Desai  
 Tel +91 22 6645 5645, Xtn 606  
 Tel Direct +91 22 66455606  
 Mobile +91 98219 23797  
 E mail [mira.desai@sunpharma.com](mailto:mira.desai@sunpharma.com)

Head Office: Plot No. 10, Sector 10, Gurgaon - 122001, India  
 Corporate Office: Sun Pharma, Andheri - Kurla Road, Andheri (East), Mumbai - 400 051, India